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Abstract: This study evaluated patients’ knowledge regarding their opioid prescriptions and identified what resources were used to educate patients 
on their opioid prescriptions.  Patients receiving an opioid prescription from an independent pharmacy were given a link to complete a nine-question 
anonymous survey about their awareness of their prescription being an opioid, how and what education they received, and from whom. The authors 
hope that the findings of this research will help to better understand effective ways to combat the opioid epidemic and promote patient safety 
through effective opioid education. 
 
 
ccording to the Centers for Disease Control and Prevention, 
deaths due to synthetic opioids other than methadone, natural 
and semisynthetic opioids, and heroin have been increasing from 
1999 to 2017.1 Approximately 92 million people in the United States use 
opioid pain relievers, and 11.5% of these individuals misuse the 
medications.2,3 Furthermore, over 47,000 opioid-related overdose 
deaths occurred in the United States in 2017.4   
 
In an effort to curb opioid addiction, dependence, and deaths, many 
regulations have been enacted regarding opioid prescriptions. On a 
national level, the Centers for Disease Control and Prevention has 
published guidelines informing providers on how to prescribe opioids 
for chronic pain.5 Currently, there is a lack of federal guidance and a 
scarcity of state regulations requiring patient labeling stating that 
medications are opioids.6 This is evident in that only five states have 
passed regulations mandating auxiliary stickers to be affixed to 
prescription bottles containing opioids.7-12 Education is a key 
component to patient awareness in regard to opioid medications. In a 
prior study by de la Cruz et al., palliative care patients were separated 
into groups where one group received educational materials 
surrounding safe opioid usage, storage, and disposal with each opioid 
prescription, whereas the other group did not receive these materials. 
The group that received the educational materials were more likely to 
keep their medications protected in a safe place while being more aware 
of proper opioid disposal methods. Additionally, this group was less 
likely to share their prescription with others, practice unsafe usage of 
opioids, or have unused medication at home.13 
 
Medical providers and pharmacists can play a critical role in providing 
meaningful education through verbal counseling. Moreover, 
pharmacists can provide written education to patients to enhance the 
retention of important information. The use of auxiliary labels and 
medication guides can provide time-saving methods for outpatient 
pharmacists to distribute information about prescription medications, 
but the extent of the benefit of these forms of communication remains 
controversial.14-17 One medication brochure study, Wolf et al., shows 
that of the studied FDA-approved medication guides, all were above the 
recommended sixth through eighth grade reading level and often failed 
to provide a summary of the content to help increase understanding of 
the content in the guide.14 Furthermore, another study by Wolf et al. 
demonstrated that of the participants who read the medication guide 
and were asked information retrieval or inference questions, the 
average participant could only recall approximately half of the 
information in the medication guide.15  
 
 
Regarding auxiliary labels, results are more positive. In a study by Gryfe-
Becker et al., when providing elderly patients with either an auxiliary 
label and counseling, an auxiliary label without counseling, counseling 
without an auxiliary label, or no counseling nor auxiliary label, it was 
found that individuals who received auxiliary labels were better able to 
correctly and completely recall the information on the label as opposed 
to the group that received no label or counseling (p=0.018).16 
Furthermore, in a study conducted by Brown et al. in patients who 
received additional auxiliary labels, 13.2% more patients were able to 
recall questions about their medication compared to subjects who did 
not receive an additional auxiliary label.17  
 
Our study sought to provide patients who were picking up prescriptions 
for opioids in an independent community pharmacy setting with 
additional information regarding their medications. Patients were 
provided with an auxiliary label on their prescription bottles detailing 
that a medication was an opioid and an educational opioid brochure. 
The purpose of this study was to evaluate patients’ knowledge regarding 
their opioid prescriptions and to assess what resources educated these 
patients on their opioid prescriptions. A literature search in Google 
Scholar and PubMed was conducted to find studies similar to that of our 
design. To the authors’ knowledge, this is the first study to evaluate 
patient knowledge and to assess the methods by which patients receive 
education regarding their opioid prescriptions.  
 
Methods 
A descriptive analysis study in 2019 was conducted. The development of 
an anonymous nine question Skip Logic survey on QualtricsTM (version 
2015) was created by the researchers and provided to eight healthcare 
providers to pilot the survey and provide feedback on content, question 
understanding, and ease of use. Through examination of responses, 
questions were refined, removed, or remained for the final survey.  
 
The study was conducted at an independent community pharmacy in 
spring 2019 and was approved by the Institutional Review Board of 
Butler University. Patients using this pharmacy who were at least 18 
years old and received at least one opioid prescription during this time 
period were eligible for inclusion in the study.  An auxiliary label stating, 
“High-Risk Medication OPIOID” was affixed to the opioid prescription 
bottle to inform patients that their prescriptions were opioids. Patients 
were given an educational brochure to inform them about the effects, 
storage, alternative treatments, and proper methods for discarding 
unused opioid medications. Patients were contacted after one week of 
receiving their prescriptions to complete an anonymous nine question 
Skip Logic QualtricsTM survey. Patients completing the survey answered 
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questions regarding demographics, knowledge of opioids, the prescriber 
of their prescriptions, and how they were educated about their opioid 
prescriptions. A maximum of three attempts were made to reach 




Eighteen of the nineteen patients contacted completed the survey for a 
response rate of 94.7%. The full quantitative question set used in the 
survey along with the responses obtained is reported below in Table 1.  
 
Table 1. Quantitative Survey questions with responses  
Question Survey Responses (Percent) n=18 patients 
1. Are you aware that a 
medication of yours is an 
opioid? 
Yes-17 (94.4%) 
No- 0 (0%) 
Prefer not to respond-1 (5.6%) 
2. Who prescribed you your 
opioid pain medication? 
Physician- 16 (88.9%) 
Physician Assistant- 0 (0%) 
Nurse Practitioner- 1 (5.6%) 
Dentist- 0 (0%) 
Other- 1 (5.6%) 
I don’t know- 0 (0%) 
Prefer not to respond- 0 (0%) 
3. How were you made 
aware that your medication 
was an opioid?  (Select all 
that apply) 
Prescriber- 8 (44.4%) 
Pharmacist- 5 (27.8%)    
Opioid sticker on bottle- 3 (16.7%)   
Opioid brochure- 0 (0%)  
Family member or friend- 1 (5.6%)  
Caregiver- 0 (0%)  
Other- 6 (33.3%) 
I was not made aware that a medication was an 
opioid- 0 (0%)  
Prefer not to respond- 0 (0%) 
4. Who/what educated you 
on your opioid 
medication?  (Select all that 
apply) 
 
Physician- 10 (55.6%) 
Pharmacist- 3 (16.7%) 
Opioid brochure- 0 (0%) 
Family member or friend- 0 (0%) 
Caregiver- 0 (0%)  
Other- 6 (33.3%) 
I was not educated on my opioid medication- 3 
(16.7%) 
Prefer not to respond- 0 (0%) 
5. What were you educated 
on regarding your 
medication? (Select all that 
apply) 
 
What an opioid is- 8 (44.4%) 
How/when to take your medication- 9 (50%) 
Alternative non-opioid medications for pain- 2 (11.1%) 
Alternative non-medication treatments for pain- 3 
(16.7%) 
How to store your medication- 3 (16.7%) 
How to dispose of your medication- 3 (16.7%) 
Side effects of your medication- 7 (38.9%) 
Other- 3 (16.7%) 
None of the above/I was not educated on this 
medication- 2 (11.1%) 
Prefer not to respond- 0 (0%) 
6. Who/what answered your 
questions regarding your 
medication?  (Select all that 
apply) 
 
Prescriber- 8 (44.4%)  
Pharmacist- 7 (38.9%)   
Opioid brochure- 0 (0%)   
Family member or friend- 0 (0%)  
Caregiver- 0 (0%) 
Other- 2 (11.1%)  
I did not have any medication questions- 3 (16.7%)   
My medication questions were not answered- 0 (0%)   
Prefer not to respond- 0 (0%) 
7. Do you have Medicare? 
 
Yes- 12 (66.7%),  
No- 5 (27.8%),   
Prefer not to respond- 1 (5.6%) 
8. What is your age? 
 
18-25- 1 (5.6%)  
26-39- 3 (16.7%)    
40-65- 8 (44.4%) 
65+- 6 (33.3%)   
Prefer not to respond- 0 (0%) 
 
In this study, patients were assessed on awareness of their opioid 
prescriptions, followed by who was involved in their care and what 
education they received. Almost all patients were aware that the 
medications they were taking were opioids, with 94.4% acknowledging 
this fact and 5.6% choosing not to respond. When asked who prescribed 
the medication, the majority of patients responded from a physician 
(88.9%) with one response each for nurse practitioner (5.6%) and 
oncologist pain specialist (5.6%). Patients were asked to select all the 
methods they were made aware of the medication being an opioid. 
Being informed by a prescriber (44.4%) was the top selection, followed 
by pharmacist (27.8%), the opioid auxiliary sticker (16.7%), and being 
told by family and friends (5.6%). Six respondents choose other and self-
reported general knowledge, life experience, and prior long-term use of 
the medication as the method of being made aware the medication was 
an opioid. Regarding how they obtained education about the product, 
55.6% reported the physician and 16.7% reported education provided 
by the pharmacist.  Three (16.7%) of the patients who selected “Other” 
reported self-education, and three (16.7%) selected they were not 
educated on their opioid medication. The top two education topics 
respondents selected were how to take the medication and what is an 
opioid (complete results are in Table 1, question 5). When patients 
asked questions about their opioids, physicians (44.4%) and pharmacists 
(38.9%) were the top answers. When asked what additional comments 
and questions patients had, one patient reported attempting to taper 
their hydrocodone prescription unsuccessfully, commenting that they 
started taking opioids 30 years ago when there was no awareness 
training at that time, and one patient asked about how long opioids stay 
in the body.  
 
Discussion 
The results of this study agree with the findings of similar studies in this 
field while also validating legislative efforts on improving patient safety. 
This study indicates that opioid auxiliary stickers provided opioid 
awareness. This finding was similar to the findings of the study 
performed by de la Cruz et al.13 In addition, various legislative actions 
have taken place on a state and national level to improve opioid 
awareness with the requirement of labeling now mandatory by law. At 
least 5 states have passed legislation requiring opioid warning labels, 
and the Lessening Addiction by Enhancing Labeling (LABEL) Opioids Act 
was introduced as a bill in the United States Congress in May 2019 (H.R. 
2732).6-12   
 
Despite the benefits of written education, verbal patient education by 
health care providers was shown to be more important for enhancing 
awareness surrounding opioid prescriptions. This result highlights the 
importance of health care providers educating their patients about 
important medication information, including communicating risks and 
ensuring safe usage of these prescriptions. While this study reinforces 
the benefits of auxiliary stickers, it casts a more questionable light on 
pamphlets as a beneficial source of education. The authors of this study 
hypothesize that this may be due to patients not reading brochures 
because of their excessive length. Previous studies have questioned the 
utility and efficacy of medication guides, and this study also questions 
the benefits of patient-centered brochures in providing meaningful 
patient education.15 In the future, healthcare practitioners may want to 
emphasize using brief yet concise written resources to educate patients 
on their opioid medications.  
 
A concern found in this study was that 16.7% of the patients were not 
educated regarding their opioid medications and another 16.7% 
patients claimed they discovered their medications were opioids by 
personal research. Patients may seek information on the internet 
instead of evidence-based information provided to them by a health 
care practitioner. Overall, this study reinforces the necessity of direct 
patient communication from a health care professional and the use of 
auxiliary labels. However, there are some limitations in this study. The 
small number of participants limits the generalizability of the results. 
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The study did not differentiate whether the patient’s opioid prescription 
was a first-time fill or a refill. Future research with a larger sample size 
involving multiple pharmacies and additional information, including 
where patients obtain information online and if the prescription was a 
first-time fill or refill, is needed.  
 
Conclusion 
This study found that a majority of patients were aware their medication 
was an opioid.  While the auxiliary sticker aided in making patients 
aware of their opioid prescription, health care professionals such as 
prescribers and pharmacists played the larger role in providing this 
awareness and educating the patients. Furthermore, although the 
brochures contained important content, no patient reported using this 
as a resource for education. Findings suggest direct communication 
from health care professionals play the major role in educating patients 
on opioid medications. Health profession schools should emphasize 
opioid education and counseling. Findings from this study and 
subsequent studies could encourage further legislation and regulation 
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